Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.48 |
| ▸ | P2RY1 | P47900 | 9/20 | 0.45 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20724524 | 0.93 | P2RY1 (0.50) | NT5EADORA3ADORA1ADORA2BP2RY1 | |
| SCHEMBL20724380 | 0.93 | P2RY1 (0.51) | NT5EADORA3ADORA1ADORA2BP2RY1 | |
| SCHEMBL20724544 | 0.93 | P2RY1 (0.51) | NT5EADORA3ADORA1ADORA2BP2RY1 | |
| SCHEMBL20724404 | 0.82 | ADORA3 (0.47) | NT5EADORA3ADORA1ADORA2B | |
| SCHEMBL20724406 | 0.80 | P2RY1 (0.43) | NT5EP2RY1P2RY2 | |
| SCHEMBL20724581 | 0.80 | ADORA3 (0.50) | NT5EADORA3ADORA1ADORA2B | |
| SCHEMBL20724479 | 0.80 | ADORA3 (0.50) | NT5EADORA3ADORA1ADORA2B | |
| SCHEMBL21136490 | 0.79 | NT5E (0.71) | NT5EADORA3ADORA1 | |
| SCHEMBL21136887 | 0.79 | NT5E (0.71) | NT5EADORA3ADORA1 | |
| SCHEMBL20724586 | 0.79 | ADORA3 (0.51) | NT5EADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202412-B2 | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections | Atea Pharmaceuticals, Inc. (US) | 2019-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202412-B2 | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections | MTAP, NSUN2, PNP | NT5E 196/4885ADORA3 89/4885ADORA1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.